Pharmaxis touts progress in cystic fibrosis study

By Ruth Beran
Monday, 19 December, 2005

Sydney-based drug developer Pharmaxis (ASX:PXS, Nasdaq:PXSL) has begun the dosing phase of its phase II clinical trial in patients with cystic fibrosis.

The study, which aims to determine the benefits of Bronchitol in children also receiving the market leading treatment, rhDNase, is being conducted at two sites in the UK.

The 42 patients enrolled in the study will receive three months treatment with each of three different therapies -- Bronchitol alone, both Bronchitol and rhDNase together and rhDNase alone. The trial will measure changes in lung function, airway inflammation, infections, and quality of life.

Full patient recruitment is expected to take about eight months

Related News

Free meningococcal B vaccines coming to the NT

The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd